Funder: Food and Drug Administration
Due Dates: September 21, 2025 (Letter of Intent) | October 21, 2025 (Application)
Funding Amounts: Up to $650,000 total costs/year (direct + indirect) for up to 4 years; up to $900,000/year for innovative trial designs with justification.
Summary: Supports clinical trials of products for new indications or labeling changes to address unmet needs in rare neurodegenerative diseases in adults and children.
Key Information: Only clinical trials are eligible; foreign and domestic applicants may apply; strict page limits and FDA-specific review criteria apply.